Pfizer has announced that its Braftovi (encorafenib) regimen significantly improved both progression-free and overall ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...

Analysts expect the New York-based company to report quarterly earnings at 46 cents per share, up from 10 cents per share in ...

Ono Pharmaceutical (OTCMKTS:OPHLF – Get Free Report) posted its quarterly earnings data on Monday. The company reported $0.21 EPS for the quarter, Zacks reports. Ono Pharmaceutical had a net margin of ...

Potential impacts of the tariffs include higher prices for drugs and medical supplies, and possible shortages.

The CEO said last month that the drugmaker had cut costs, revamped its sales operation, and made other big fixes.

BRAFTOVI's FDA Approval Sparks Hope for BRAF V600E-mutant Colorectal Cancer Patients and Sets Pfizer Up for Explosive Growth ...

Pfizer (PFE) is set to announce Q4 earnings, with analysts expecting a $0.46 profit per share and $17.26B revenue.

Phar­ma­ceu­ti­cal in­dus­try groups cau­tion that Pres­i­dent Don­ald Trump’s tar­iffs on Chi­na, Mex­i­co and Cana­da will ...

Pfizer (NYSE:PFE) reported positive topline results from a Phase 3 study of its drug Braftovi, also known as encorafenib, in the treatment of a certain type of colorectal cancer. The study, called ...

Allot's growth prospects remain unclear due to revenue unpredictability. Find out why ALLT stock is risky given its untested ...